You eat right, exercise, and still develop diabetes. Here's why.

TCF7L2 is a transcription factor, a molecular switch that turns genes on and off. Specifically, it controls genes involved in incretin signaling,the mechanism by which your intestines signal your pancreas to release insulin when you eat carbs. When TCF7L2 is working normally, glucose rises, your intestines release hormones called incretins, those hormones trigger TCF7L2 activation, and your beta cells release insulin.

The T allele at rs7903146 disrupts this signaling chain. Roughly 30% of the population carries at least one copy. People with the T allele show impaired incretin-stimulated insulin secretion, meaning their pancreas doesn’t respond as sharply when blood glucose rises after eating. The effect is subtle at first,fasting glucose might be normal, but post-meal glucose spikes higher and stay elevated longer.

Over time, this compounds. Your body compensates by producing more insulin overall (hyperinsulinemia), which taxes your beta cells and increases insulin resistance throughout your tissues. You might eat a low-carb diet and still see fasting glucose in the high-normal range (105-110 mg/dL) where it should be under 100. You feel fine, your doctor says everything looks okay, but your beta cells are already working harder than they should be.

Your pancreatic beta cells have melatonin receptors on them. Melatonin, the hormone that makes you sleepy at night, also tells your pancreas to dial down insulin secretion. This makes biological sense: at night, you’re not eating, so you don’t need insulin. Melatonin keeps insulin low so your body can use its own glucose stores.

The G allele at rs10830963 amplifies this melatonin-mediated suppression. Approximately 30% of the population carries at least one copy. People with the G allele show exaggerated insulin suppression in response to melatonin, and their fasting glucose is measurably higher than people without the variant. Some research suggests this effect is strongest in people who are overweight or have metabolic syndrome.

You might notice your fasting glucose is always slightly elevated, even after a night of good sleep. You cut carbs, your post-meal glucose improves, but that fasting number (which your doctor uses to diagnose pre-diabetes) refuses to budge below 105 mg/dL. That’s the MTNR1B effect: melatonin is suppressing overnight insulin, so your liver continues releasing glucose into the bloodstream unchecked.

Inside your pancreatic beta cells, an ATP-sensitive potassium channel acts as a glucose sensor. When glucose enters the cell, ATP (energy) builds up, which closes the channel and triggers insulin release. This is the core mechanism: glucose goes in, ATP rises, potassium channel closes, insulin comes out.

The K allele at rs5219 impairs this channel’s ability to close in response to ATP. Roughly 35-40% of the population carries at least one copy. People with the K allele show reduced ATP-sensitive channel closure, meaning their beta cells don’t respond as sharply to glucose, and they secrete less insulin in the critical first few minutes after a meal. This is called a delayed or blunted first-phase insulin response.

You eat a meal, your glucose rises, but your pancreas is slow to respond. By the time insulin arrives in the bloodstream, glucose has already spiked higher than optimal. You might see post-meal glucose readings of 160-180 mg/dL even on a moderate-carb meal, when someone without the variant would peak at 130 mg/dL. Fasting glucose might be normal because your liver is still responsive, but the moment you eat, the deficit shows.

Zinc is not glamorous, but it’s critical. Your pancreatic beta cells use zinc to crystallize and package insulin for storage in vesicles. When glucose triggers insulin secretion, those vesicles fuse with the cell membrane and release the crystallized insulin. No zinc, no proper crystallization. No crystallization, no proper storage or release.

The W allele at rs13266634 impairs the zinc transporter SLC30A8. Roughly 30% of the population carries at least one copy. People with the W allele show reduced zinc transport into beta cells, which impairs insulin crystallization and secretion, particularly during the second phase of the insulin response (the sustained release after the initial spike). First-phase insulin might be okay; second-phase falters.

You eat a meal and your glucose rises. The first burst of insulin is adequate. But then your glucose plateaus at a high level (140-150 mg/dL) for 2-3 hours instead of dropping back down. Your body can’t sustain the insulin output needed to clear that glucose. You feel an energy dip after eating,not hypoglycemia, but the metabolic fatigue of a prolonged glucose elevation and the effort your body is making to manage it.

PPARG is a master regulator of fat cell biology. It controls how efficiently your body stores fat in adipose tissue and how sensitive your fat cells (and muscle) are to insulin’s signal. The more efficient your fat storage, the lower your insulin requirements should theoretically be.

But here’s the catch: the Pro12 allele at the Pro12Ala position promotes very efficient fat storage. Roughly 25% of the population carries at least one copy. People with the Pro12 allele store fat very efficiently, but this metabolic efficiency is associated with impaired insulin sensitivity and resistance to dietary interventions aimed at weight loss or metabolic improvement. They gain weight easily and lose it slowly.

You eat the same amount as a friend with the Ala12 allele, but your body stores more of it as fat. Your friend loses 10 pounds on a low-carb diet; you lose 2. Your insulin sensitivity doesn’t improve proportionally because your genetic predisposition overrides the dietary signal. Your fasting glucose and insulin don’t drop as much as expected, and your triglycerides stay stubbornly elevated. It’s not laziness. Your genes are fighting against you.

Insulin binds to the insulin receptor on the outside of your muscle and fat cells. But the signal has to travel inside the cell to actually lower blood glucose. IRS1 (insulin receptor substrate 1) is the molecular relay station. Insulin receptor activates it, and IRS1 propagates the signal downstream, telling muscle cells to take up glucose from the bloodstream.

The variant at rs2943641 reduces IRS1 expression, meaning fewer relay stations are available. Roughly 35% of the population carries at least one copy. People with this IRS1 variant show reduced downstream insulin signaling and impaired glucose uptake in muscle tissue; the same dose of insulin is less effective at lowering glucose. Your cells are less insulin-sensitive not because they’re resistant from obesity, but because the genetic relay is understaffed.

You might have normal or even high insulin levels (hyperinsulinemia) but still elevated glucose. Your body is producing plenty of insulin; it’s just not getting through the communication channel efficiently. You feel the metabolic cost: fatigue after meals, energy crashes, constant hunger because your cells aren’t properly receiving the nutrient signal that glucose has arrived.